(SNN) Smith & Nephew SNATS - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US83175M2052
Stock: Implants, Repair, Wound Care, Surgical Tools
Total Rating 49
Risk 79
Buy Signal -0.67
| Risk 5d forecast | |
|---|---|
| Volatility | 27.2% |
| Relative Tail Risk | -11.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 9.12 |
| Character TTM | |
|---|---|
| Beta | 0.214 |
| Beta Downside | 0.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.29% |
| CAGR/Max DD | 0.28 |
EPS (Earnings per Share)
Revenue
Description: SNN Smith & Nephew SNATS March 05, 2026
Smith & Nephew plc (SNN) develops and sells medical devices globally, with operations in the United Kingdom and United States.
The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. This structure reflects the diversified nature of the medical device industry.
SNNs product offerings include knee and hip implants, trauma and extremities products, and other reconstruction solutions. The orthopedic sector is a significant part of the medical device market due to an aging global population.
The Sports Medicine & ENT segment provides minimally invasive surgery tools, soft tissue injury treatments, and arthroscopic enabling technologies. Minimally invasive procedures are a growing trend in healthcare.
The Advanced Wound Management segment focuses on acute and chronic wound care, including bioactives and negative pressure wound therapy. Wound care is an essential component of post-operative recovery and chronic disease management.
SNN serves healthcare providers and was founded in 1856, headquartered in Watford, UK. Further research on ValueRay can provide more detailed financial and operational insights.
Headlines to watch out for
- Orthopaedics segment revenue growth drives overall company performance
- Sports Medicine & ENT product innovation expands market share
- Advanced Wound Management sales contribute to diversified revenue
- Regulatory approvals for new medical devices impact market entry
- Healthcare spending trends influence demand for elective procedures
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 814.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.42 > 1.0 |
| NWC/Revenue: 30.20% < 20% (prev 21.13%; Δ 9.06% < -1%) |
| CFO/TA 0.14 > 3% & CFO 1.51b > Net Income 814.6m |
| Net Debt (2.78b) to EBITDA (2.22b): 1.25 < 3 |
| Current Ratio: 3.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (439.9m) vs 12m ago -49.60% < -2% |
| Gross Margin: 69.95% > 18% (prev 0.70%; Δ 6925 % > 0.5%) |
| Asset Turnover: 98.80% > 50% (prev 83.34%; Δ 15.46% > 0%) |
| Interest Coverage Ratio: 4.98 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m) |
Altman Z'' 5.29
| A: 0.29 (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b |
| B: 0.48 (Retained Earnings 5.12b / Total Assets 10.68b) |
| C: 0.12 (EBIT TTM 1.27b / Avg Total Assets 10.33b) |
| D: 0.96 (Book Value of Equity 4.96b / Total Liabilities 5.15b) |
| Altman-Z'' Score: 5.29 = AAA |
Beneish M -2.83
| DSRI: 1.14 (Receivables 1.48b/1.06b, Revenue 10.21b/8.32b) |
| GMI: 1.00 (GM 69.95% / 70.14%) |
| AQI: 0.96 (AQ_t 0.43 / AQ_t-1 0.45) |
| SGI: 1.23 (Revenue 10.21b / 8.32b) |
| TATA: -0.06 (NI 814.6m - CFO 1.51b) / TA 10.68b) |
| Beneish M-Score: -2.83 (Cap -4..+1) = A |
What is the price of SNN shares?
As of March 09, 2026, the stock is trading at USD 34.31 with a total of 734,749 shares traded.
Over the past week, the price has changed by -4.05%, over one month by -2.14%, over three months by +2.45% and over the past year by +18.25%.
Over the past week, the price has changed by -4.05%, over one month by -2.14%, over three months by +2.45% and over the past year by +18.25%.
Is SNN a buy, sell or hold?
Smith & Nephew SNATS has received a consensus analysts rating of 3.75.
Therefor, it is recommend to hold SNN.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.6 | 6.7% |
| Analysts Target Price | 36.6 | 6.7% |
SNN Fundamental Data Overview March 09, 2026
P/E Trailing = 30.6339
P/E Forward = 12.8535
P/S = 2.3626
P/B = 2.672
P/EG = 0.6772
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 17.34b USD (14.56b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
EV/FCF = 19.30x (Enterprise Value 17.34b / FCF TTM 898.3m)
FCF Yield = 5.18% (FCF TTM 898.3m / Enterprise Value 17.34b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.62 (Enterprise Value 17.34b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.88% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 5.78% (E(14.56b)/V(18.01b) * Re(6.70%) + D(3.45b)/V(18.01b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -29.01%
[DCF] Terminal Value 86.99% ; FCFF base≈658.4m ; Y1≈705.2m ; Y5≈856.6m
[DCF] Fair Price = 53.20 (EV 25.36b - Net Debt 2.78b = Equity 22.58b / Shares 424.5m; r=5.90% [WACC]; 5y FCF grow 7.97% → 2.90% )
EPS Correlation: 15.81 | EPS CAGR: 282.5% | SUE: -1.97 | # QB: 0
Revenue Correlation: 30.84 | Revenue CAGR: 4.06% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.237 | Chg30d=+0.242 | Revisions Net=+2 | Growth EPS=+0.5% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.287 | Chg30d=+0.287 | Revisions Net=+1 | Growth EPS=+2.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.3%)
[Growth] Growth Spread = +0.9% (Analyst 5.6% - Implied 4.7%)
P/E Forward = 12.8535
P/S = 2.3626
P/B = 2.672
P/EG = 0.6772
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 17.34b USD (14.56b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
EV/FCF = 19.30x (Enterprise Value 17.34b / FCF TTM 898.3m)
FCF Yield = 5.18% (FCF TTM 898.3m / Enterprise Value 17.34b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.62 (Enterprise Value 17.34b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.88% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 5.78% (E(14.56b)/V(18.01b) * Re(6.70%) + D(3.45b)/V(18.01b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -29.01%
[DCF] Terminal Value 86.99% ; FCFF base≈658.4m ; Y1≈705.2m ; Y5≈856.6m
[DCF] Fair Price = 53.20 (EV 25.36b - Net Debt 2.78b = Equity 22.58b / Shares 424.5m; r=5.90% [WACC]; 5y FCF grow 7.97% → 2.90% )
EPS Correlation: 15.81 | EPS CAGR: 282.5% | SUE: -1.97 | # QB: 0
Revenue Correlation: 30.84 | Revenue CAGR: 4.06% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=2.05 | Chg7d=+0.237 | Chg30d=+0.242 | Revisions Net=+2 | Growth EPS=+0.5% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=2.09 | Chg7d=+0.287 | Chg30d=+0.287 | Revisions Net=+1 | Growth EPS=+2.0% | Growth Revenue=+5.6%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.3%)
[Growth] Growth Spread = +0.9% (Analyst 5.6% - Implied 4.7%)